Literature DB >> 19222206

Design, synthesis, and preliminary in vitro and in vivo evaluation of N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide ([18F]-DAFBA): a novel potential PET probe to image melanoma tumors.

Sudha Garg1, Kanchan Kothari, Shankar R Thopate, Aniruddha K Doke, Pradeep K Garg.   

Abstract

In order to develop a PET radiopharmaceutical to image malignant melanoma, we synthesized N-(2-diethylaminoethyl)-4-[(18)F]fluorobenzamide ([(18)F]-DAFBA). In vitro studies show a high uptake of [(18)F]-DAFBA by the B16F1 melanoma cells. No significant binding was seen for DAFBA to the sigma-1 and sigma-2 receptors in vitro. The in vivo biodistribution studies performed in normal ICR mice showed a low uptake in the normal tissues followed by further elimination of radioactivity from these tissues with time. The biodistribution studies performed in C57 mice bearing the melanoma tumor xenograft showed a rapid uptake of radioactivity in the tumor that reached a plateau within 30 min postinjection. The F-18 uptake in the tumor was 7.00 +/- 2.76, 6.57 +/- 1.66, and 5.80 +/- 0.98%ID/g at 60, 120, and 180 min, respectively. A steady uptake of radioactivity in the tumor and low uptake in normal tissues resulted in high tumor to normal tissue ratios. For example, at 180 min postinjection, the tumor to tissue ratios were 14.90 +/- 6.47, 21.90 +/- 4.68, 32.91 +/- 6.11, 39.73 +/- 11.78, and 6.33 +/- 1.9, for the spleen, lungs, muscle, blood, and liver, respectively. The radioactivity rapidly cleared from the blood pool, and it decreased from 0.68 +/- 0.21%ID/g at 60 min to 0.13 +/- 0.03%ID/g at 180 min. The F-18 uptake in the bones at 60, 120, and 180 min was 0.91 +/- 0.27, 0.57 +/- 0.32, and 0.17 +/- 0.05%ID/g, respectively. This low uptake in the bones reflects its in vivo resistance toward defluorination. A low residual activity in normal tissues and a high tumor uptake signifies the superior imaging potential of this compound. Because of these positive traits, [(18)F]-DAFBA could help delineate the tumor and its metastases when used for imaging applications. Further in vivo studies are underway to assess the potential of [(18)F]-DAFBA as a promising PET imaging probe.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19222206      PMCID: PMC2880618          DOI: 10.1021/bc8005094

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  37 in total

1.  An admonition when measuring the lipophilicity of radiotracers using counting techniques.

Authors:  A A Wilson; L Jin; A Garcia; J N DaSilva; S Houle
Journal:  Appl Radiat Isot       Date:  2001-02       Impact factor: 1.513

2.  Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma.

Authors:  K M Acland; C Healy; E Calonje; M O'Doherty; T Nunan; C Page; E Higgins; R Russell-Jones
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

3.  Baseline staging in cutaneous malignant melanoma.

Authors:  J Hafner; M Hess Schmid; W Kempf; G Burg; W Künzi; C Meuli-Simmen; P Neff; V Meyer; D Mihic; E Garzoli; K-P Jungius; B Seifert; R Dummer; H Steinert
Journal:  Br J Dermatol       Date:  2004-04       Impact factor: 9.302

4.  Limited sensitivity of iodine-123-2-hydroxy-3-iodo-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl ] benzamide whole-body scintigraphy in patients with malignant melanoma: a comparison with thallium-201 imaging.

Authors:  W Brenner; H J Klomp; K H Bohuslavizki; B Szonn; W U Kampen; E Henze
Journal:  Eur J Nucl Med       Date:  1999-12

5.  In vivo evaluation of 99mTc/188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting.

Authors:  J Chen; M F Giblin; N Wang; S S Jurisson; T P Quinn
Journal:  Nucl Med Biol       Date:  1999-08       Impact factor: 2.408

6.  Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization.

Authors:  M Eisenhut; W E Hull; A Mohammed; W Mier; D Lay; W Just; K Gorgas; W D Lehmann; U Haberkorn
Journal:  J Med Chem       Date:  2000-10-19       Impact factor: 7.446

7.  Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents.

Authors:  N Moins; J Papon; H Seguin; D Gardette; M F Moreau; P Labarre; M Bayle; J Michelot; J C Gramain; J C Madelmont; A Veyre
Journal:  Nucl Med Biol       Date:  2001-10       Impact factor: 2.408

Review 8.  Peptide-targeted radionuclide therapy for melanoma.

Authors:  Yubin Miao; Thomas P Quinn
Journal:  Crit Rev Oncol Hematol       Date:  2008-04-02       Impact factor: 6.312

9.  [Phase 2 clinical study of 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnostic of primary and metastatic ocular melanoma].

Authors:  I Sillaire-Houtmann; J Bonafous; A Veyre; D Mestas; M D'Incan; N Moins; J-L Kemeny; F Chossat; F Bacin
Journal:  J Fr Ophtalmol       Date:  2004-01       Impact factor: 0.818

10.  123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging.

Authors:  Nicole Moins; Michel D'Incan; Jacques Bonafous; Franck Bacin; Pierre Labarre; Marie-France Moreau; Danièle Mestas; Elisabeth Noirault; Florence Chossat; Eric Berthommier; Janine Papon; Martine Bayle; Pierre Souteyrand; Jean-Claude Madelmont; Annie Veyre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-09-11       Impact factor: 9.236

View more
  13 in total

Review 1.  PET and SPECT imaging of melanoma: the state of the art.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quanyong Luo; Weibo Cai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10-30       Impact factor: 9.236

2.  N-(2-(Dimethylamino)Ethyl)-4-18F-Fluorobenzamide: A Novel Molecular Probe for High-Contrast PET Imaging of Malignant Melanoma.

Authors:  Ayoung Pyo; Hyeon Sik Kim; Hyung Seok Kim; Misun Yun; Dong-Yeon Kim; Jung-Joon Min
Journal:  J Nucl Med       Date:  2018-12-14       Impact factor: 10.057

3.  Early detection and longitudinal monitoring of experimental primary and disseminated melanoma using [¹⁰F]ICF01006, a highly promising melanoma PET tracer.

Authors:  Latifa Rbah-Vidal; Aurélien Vidal; Sophie Besse; Florent Cachin; Mathilde Bonnet; Laurent Audin; Serge Askienazy; Frédéric Dollé; Françoise Degoul; Elisabeth Miot-Noirault; Nicole Moins; Philippe Auzeloux; Jean-Michel Chezal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-16       Impact factor: 9.236

4.  PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.

Authors:  Thomas Pfluger; Henriette Ingrid Melzer; Vera Schneider; Christian La Fougere; Eva Coppenrath; Carola Berking; Peter Bartenstein; Mayo Weiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

Review 5.  MC1R and melanin-based molecular probes for theranostic of melanoma and beyond.

Authors:  Hui Shi; Zhen Cheng
Journal:  Acta Pharmacol Sin       Date:  2022-08-25       Impact factor: 7.169

6.  A novel aliphatic 18F-labeled probe for PET imaging of melanoma.

Authors:  Hongguang Liu; Shuanglong Liu; Zheng Miao; Han Jiang; Zixin Deng; Xuechuan Hong; Zhen Cheng
Journal:  Mol Pharm       Date:  2013-08-22       Impact factor: 4.939

7.  Imaging malignant melanoma with (18)F-5-FPN.

Authors:  Hongyan Feng; Xiaotian Xia; Chongjiao Li; Yiling Song; Chunxia Qin; Qingyao Liu; Yongxue Zhang; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-11       Impact factor: 9.236

8.  Development of 18F-labeled picolinamide probes for PET imaging of malignant melanoma.

Authors:  Hongguang Liu; Shuanglong Liu; Zheng Miao; Zixin Deng; Baozhong Shen; Xuechuan Hong; Zhen Cheng
Journal:  J Med Chem       Date:  2013-01-18       Impact factor: 7.446

9.  Synthesis and preclinical characterization of [18F]FPBZA: a novel PET probe for melanoma.

Authors:  Shih-Yen Wu; Shih-Pin Huang; Yen-Chen Lo; Ren-Shyan Liu; Shyh-Jen Wang; Wuu-Jyh Lin; Chih-Chieh Shen; Hsin-Ell Wang
Journal:  Biomed Res Int       Date:  2014-09-01       Impact factor: 3.411

10.  Selective targeting of melanoma using N-(2-diethylaminoethyl) 4-[18F]fluoroethoxy benzamide (4-[18F]FEBZA): a novel PET imaging probe.

Authors:  Pradeep K Garg; Rachid Nazih; Yanjun Wu; Vladimir P Grinevich; Sudha Garg
Journal:  EJNMMI Res       Date:  2017-08-08       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.